Dana-Farber Research Helps Drive FDA Label Update for Primary CNS Lymphoma - Quiz - MDSpire

Dana-Farber Research Helps Drive FDA Label Update for Primary CNS Lymphoma

Change removes prior exclusion and may expand access to CAR T-cell therapy for eligible relapsed or refractory patients

  • By

  • February 9, 2026

  • 3 min

Share

Original Source(s)

Dana-Farber Research Helps Drive FDA Label Update for Primary CNS Lymphoma

  • by

  • February 9, 2026

Related Content

Artificial intelligence for optimization of immunotherapy: current applications and transformative potential

Recurrent IDH-mutant astrocytoma WHO grade 4 diagnosed during pregnancy: case report with literature review

Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment